Evidence map›Paper›PMID 26812157›Full record

ArticleEndocrinology2016

Prolonged Oral Administration of a Pan-Retinoic Acid Receptor Antagonist Inhibits Spermatogenesis in Mice With a Rapid Recovery and Changes in the Expression of Influx and Efflux Transporters.

Sanny S W Chung, Xiangyuan Wang, Debra J Wolgemuth

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Endocrinology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 45 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Non-hormonal Contraception: Current and Emerging Targets.Advances in experimental medicine and biology · 2025
    Review
  6. Review
  7. Review
  8. Targeting nuclear receptor corepressors for reversible male contraception.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Emerging approaches to male contraception.Fertility and sterility · 2021
    Review
  17. Update on Novel Hormonal and Nonhormonal Male Contraceptive Development.The Journal of clinical endocrinology and metabolism · 2021
    Review
  18. Cell cycle (Georgetown, Tex.) · 2020
    Review
  19. Male Contraception.The Yale journal of biology and medicine · 2020
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Sanny S W ChungDepartments of Genetics and Development (S.S.W.C., X.W., D.J.W.) and Obstetrics and Gynecology (D.J.W.), The Institute of Human Nutrition (D.J.W.), and The Herbert Irving Comprehensive Cancer Center (D.J.W.), Columbia University Medical Center, New York, New York 10032.
Xiangyuan WangDepartments of Genetics and Development (S.S.W.C., X.W., D.J.W.) and Obstetrics and Gynecology (D.J.W.), The Institute of Human Nutrition (D.J.W.), and The Herbert Irving Comprehensive Cancer Center (D.J.W.), Columbia University Medical Center, New York, New York 10032.
Debra J WolgemuthDepartments of Genetics and Development (S.S.W.C., X.W., D.J.W.) and Obstetrics and Gynecology (D.J.W.), The Institute of Human Nutrition (D.J.W.), and The Herbert Irving Comprehensive Cancer Center (D.J.W.), Columbia University Medical Center, New York, New York 10032.
Columbia University Irving Medical Center · US

Funding

PROJECT 3 - Steroid-Metabolic Interactions In the Control of GnRH NeuronsU54HD028934 · NICHD · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI HAISENLEDER, DANIEL J. · 1998 to 2013
$16.5M
Retinoid Receptor Antagonists as Novel Male ContraceptivesU01HD060479 · NICHD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI WOLGEMUTH, DEBRA J. · 2009 to 2018
$2.7M
NICHD NIH HHS U01 HD060479NICHD NIH HHS U01-HD060479NICHD NIH HHS U54 HD028934NICHD NIH HHS U54-HD28934
6 · The paper itself

Abstract

We have previously shown that oral administration of a pan-retinoic acid receptor antagonist in mice daily at 2.5 mg/kg for 4 weeks reversibly inhibited spermatogenesis, with no detectable side effects. To elucidate the lowest dose and the longest dosing regimen that inhibits spermatogenesis but results in complete restoration of fertility upon cessation of administration of the drug, we examined the effects of daily doses as low as 1.0 mg/kg with dosing periods of 4, 8, and 16 weeks. We observed 100% sterility in all regimens, with restoration of fertility upon cessation of the drug treatment even for as long as 16 weeks. There was no change in testosterone levels in these males and the progeny examined from 2 of the recovered males were healthy and fertile, with normal testicular weight and testicular histology. Strikingly, a more rapid recovery, as assessed by mating studies, was observed at the lower dose and longer dosing periods. Insight into possible mechanisms underlying this rapid recovery was obtained at 2 levels. First, histological examination revealed that spermatogenesis was not as severely disrupted at the lower dose and with the longer treatment regimens. Second, gene expression analysis revealed that the more rapid recovery may involve the interplay of ATP-binding cassette efflux and solute carrier influx transporters in the testes.

Indexed as

Administration, OralAnimalsATP-Binding Cassette TransportersCarrier ProteinsDose-Response Relationship, DrugFemaleFertilityGene ExpressionImmunohistochemistryMaleMembrane ProteinsMembrane Transport ProteinsMiceMicroscopy, FluorescenceOrganic Anion Transporters, Sodium-IndependentOrganic Cation Transport ProteinsATP-Binding Cassette TransportersBMS 189453Carrier ProteinsMembrane ProteinsMembrane Transport ProteinsOrganic Anion Transporters, Sodium-IndependentOrganic Cation Transport ProteinsReceptors, Retinoic AcidRetinoidsSlc22a4 protein, mouseSlc22a7 protein, mouseSymportersTestosterone

Identifiers

PMID26812157
PMCPMC4816726
OpenAlexW2268010945

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.